Form 8-K - Current report:
SEC Accession No. 0001493152-22-009991
Filing Date
2022-04-15
Accepted
2022-04-14 20:20:29
Documents
21
Period of Report
2022-04-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 54384
2 ex4-1.htm EX-4.1 117960
3 ex5-1.htm EX-5.1 67044
4 ex10-1.htm EX-10.1 236202
5 ex99-1.htm EX-99.1 11967
6 ex99-2.htm EX-99.2 11264
7 ex5-1_001.jpg GRAPHIC 12266
8 ex5-1_002.jpg GRAPHIC 6283
9 ex5-1_004.jpg GRAPHIC 10219
  Complete submission text file 0001493152-22-009991.txt   856151

Data Files

Seq Description Document Type Size
10 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lixt-20220412.xsd EX-101.SCH 3532
11 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lixt-20220412_def.xml EX-101.DEF 26835
12 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lixt-20220412_lab.xml EX-101.LAB 36810
13 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lixt-20220412_pre.xml EX-101.PRE 25457
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5178
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 22828751
SIC: 2834 Pharmaceutical Preparations